Trial Condition(s):

Diabetes Mellitus, Type 2

To evaluate clinical outcome and injection compliance of Scilin (SEAS)

Bayer Identifier:

16372

ClinicalTrials.gov Identifier:

NCT01588639

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This is a prospective, multi-center, open-label, non-interventional, 12-week study in people with type 2 diabetes mellitus who are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice. The term study insulins will be used in this protocol for these drugs and combinations.

Inclusion Criteria
- Based on  physicians’ clinical judgement, subjects who are treated with SciLin N, SciLin R and SciLin M30 ( alone or in combination) will be eligible to be included in this clinical study.
Exclusion Criteria
Subjects with one of the conditions listed below will be excluded:
Women who are pregnant, breast feeding or have the intention of becoming pregnant within the next 6 months
Subjects who have to be treated with other insulins simultaneously 
Subjects who are participating in other diabetes clinical studies at the same time

Trial Summary

Enrollment Goal
2683
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
SciLin (Human recombinant insulin, BAY81-9924)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, China

Status
Completed
 

Trial Design